Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Mallinckrodt
Merck
McKinsey
Harvard Business School

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR ILOPROST


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Iloprost

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004786 ↗ Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed University of Pittsburgh Phase 3 1995-12-01 OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis.
NCT00004786 ↗ Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis Completed National Center for Research Resources (NCRR) Phase 3 1995-12-01 OBJECTIVES: I. Evaluate the safety and efficacy of oral iloprost, a prostacyclin analog, in patients with Raynaud's phenomenon secondary to systemic sclerosis.
NCT00084409 ↗ Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease Completed National Cancer Institute (NCI) Phase 2 2001-11-01 RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Iloprost may be effective in preventing lung cancer. PURPOSE: This randomized phase II trial is studying how well iloprost works in preventing lung cancer in patients who are at high risk for this disease.
NCT00084409 ↗ Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease Completed University of Colorado, Denver Phase 2 2001-11-01 RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Iloprost may be effective in preventing lung cancer. PURPOSE: This randomized phase II trial is studying how well iloprost works in preventing lung cancer in patients who are at high risk for this disease.
NCT00086463 ↗ Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH) Completed Actelion Phase 2 2004-06-01 The purpose of this study is to determine the safety and efficacy of Iloprost in subjects that have Pulmonary Arterial Hypertension who are concurrently taking bosentan (Tracleer TM).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Iloprost

Condition Name

Condition Name for Iloprost
Intervention Trials
Pulmonary Hypertension 23
Pulmonary Arterial Hypertension 19
Hypertension, Pulmonary 8
Chronic Obstructive Pulmonary Disease 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Iloprost
Intervention Trials
Hypertension 54
Hypertension, Pulmonary 36
Pulmonary Arterial Hypertension 28
Familial Primary Pulmonary Hypertension 28
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Iloprost

Trials by Country

Trials by Country for Iloprost
Location Trials
United States 217
Germany 43
China 14
Japan 11
France 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Iloprost
Location Trials
California 16
Pennsylvania 13
Texas 12
New York 12
Illinois 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Iloprost

Clinical Trial Phase

Clinical Trial Phase for Iloprost
Clinical Trial Phase Trials
Phase 4 13
Phase 3 15
Phase 2/Phase 3 5
[disabled in preview] 30
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Iloprost
Clinical Trial Phase Trials
Completed 52
Terminated 14
Unknown status 11
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Iloprost

Sponsor Name

Sponsor Name for Iloprost
Sponsor Trials
Actelion 17
Bayer 16
Yonsei University 5
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Iloprost
Sponsor Trials
Other 89
Industry 43
NIH 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Baxter
AstraZeneca
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.